Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Breast Cancer
NCT07824869Phase 2Not yet recruiting
- Sponsor
- Henlius
- Start
- Oct 2026
- Primary completion
- Mar 2028
01
Overview
A Phase 2 trial of hlx22 in breast cancer, sponsored by Henlius. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
hlx22
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07824869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07824869.